初诊CNS2型B-ALL诱导期增加鞘内阿糖胞苷未改善结局
研究基于COG AALL0932和AALL1131试验,评估初诊CNS2型B-ALL患者在诱导期增加鞘内阿糖胞苷的疗效。结果显示,额外鞘内阿糖胞苷未改善无事件生存、总生存或降低复发累积发生率,多因素分析未发现显著获益亚群。未来COG B-ALL研究将不再对CNS2患者诱导期增加鞘内阿糖胞苷。
要点
- 诱导期增加鞘内阿糖胞苷未改善CNS2型B-ALL患者的结局。
- 多因素分析未发现从额外鞘内阿糖胞苷中显著获益的亚群。
- 未来COG研究将不再对CNS2患者诱导期增加鞘内阿糖胞苷。
核心结论
- 初诊CNS2型B-ALL诱导期增加鞘内阿糖胞苷未改善结局,也未减轻CNS2状态的不良预后影响。
研究设计与样本
- 基于COG AALL0932和AALL1131试验,比较修正案前后CNS2型B-ALL患者,按3药(标危)或4药(高危)诱导分层。
主要发现
- 修正案前后CNS2患者的人口学和疾病特征无显著差异。
- 额外鞘内阿糖胞苷未改善无事件生存、总生存或复发累积发生率。
- 多因素分析调整疾病预后因素、种族/民族和白血病细胞遗传学后,未发现显著获益亚群。
临床怎么用
- 初诊CNS2型B-ALL诱导期不应常规增加鞘内阿糖胞苷。
- CNS2状态仍提示不良预后,需探索替代治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with central nervous system (CNS) disease at diagnosis on Children's Oncology Group (COG) B-acute lymphoblastic leukemia (B-ALL) trials AALL0331 and AALL0232 had inferior outcomes, largely secondary to CNS relapse. In response, for patients with newly diagnosed B-ALL enrolled on COG studies AALL0932 and AALL1131, therapy was adjusted to incorporate additional intrathecal cytarabine during induction for patients with low-level CNS involvement (CNS2). We evaluated the impact of this intervention.Event-free survival, overall survival, and cumulative incidence of relapse were compared among patients with CNS2 B-ALL before vs after amendment, stratified by receipt of a 3-drug (standard-risk) or 4-drug (high-risk) induction. Multivariable models were constructed to adjust for demographic and disease variables. When stratified by trial, preamendment and postamendment patients with CNS2 status did not differ significantly by demographic or disease factors. Additional intrathecal cytarabine doses during induction did not improve outcomes for patients with B-ALL. Multivariate analyses adjusting for disease prognosticators, race/ethnicity, and leukemia cytogenetics did not identify any subpopulation that significantly benefited from additional intrathecal cytarabine. Additional intrathecal cytarabine during induction for patients with CNS2 B-ALL did not improve outcomes or mitigate the adverse prognostic impact of CNS2 status in B-ALL. Future COG B-ALL studies will not include additional intrathecal cytarabine in induction for patients with CNS2 disease. Alternative treatment strategies are needed for patients with CNS2 disease.
引用
- Lee-Miller CA, Kairalla JA, Hibbitts E, et al. Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes. Blood Adv. 2026. PMID: 41984995. doi:10.1182/bloodadvances.2026019660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。